federal_register: 2016-13165

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
2016-13165 Expanded Access to Investigational Drugs for Treatment Use-Questions and Answers; Guidance for Industry; Availability Notice The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled "Expanded Access to Investigational Drugs for Treatment Use--Questions and Answers." The guidance provides information for industry, researchers, physicians, institutional review boards (IRBs), and patients about the implementation of FDA's regulations on expanded access to investigational drugs for treatment use under an investigational new drug application (IND). FDA received a number of questions concerning implementation of its expanded access regulations and is providing guidance in a question and answer format to address the most frequently asked questions. This guidance finalizes the draft guidance issued in May 2013. 2016-06-03 2016 6 https://www.federalregister.gov/documents/2016/06/03/2016-13165/expanded-access-to-investigational-drugs-for-treatment-use-questions-and-answers-guidance-for https://www.govinfo.gov/content/pkg/FR-2016-06-03/pdf/2016-13165.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled "Expanded Access to Investigational Drugs for Treatment Use--Questions and Answers." The guidance provides information for industry,...  

Links from other tables